TWI676636B - 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子 - Google Patents
包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子 Download PDFInfo
- Publication number
- TWI676636B TWI676636B TW103123759A TW103123759A TWI676636B TW I676636 B TWI676636 B TW I676636B TW 103123759 A TW103123759 A TW 103123759A TW 103123759 A TW103123759 A TW 103123759A TW I676636 B TWI676636 B TW I676636B
- Authority
- TW
- Taiwan
- Prior art keywords
- virus
- antigen
- seq
- pharmaceutical composition
- amino acid
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 216
- 239000000427 antigen Substances 0.000 title claims abstract description 201
- 108091007433 antigens Proteins 0.000 title claims abstract description 201
- 102000036639 antigens Human genes 0.000 title claims abstract description 201
- 239000003446 ligand Substances 0.000 title claims abstract description 64
- 241000700605 Viruses Species 0.000 title claims description 71
- 108010087302 Viral Structural Proteins Proteins 0.000 claims abstract description 84
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 230000028993 immune response Effects 0.000 claims abstract description 13
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 107
- 241001502567 Chikungunya virus Species 0.000 claims description 100
- 239000008194 pharmaceutical composition Substances 0.000 claims description 64
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 63
- 102000039446 nucleic acids Human genes 0.000 claims description 49
- 108020004707 nucleic acids Proteins 0.000 claims description 49
- 150000007523 nucleic acids Chemical class 0.000 claims description 49
- 239000002773 nucleotide Substances 0.000 claims description 43
- 125000003729 nucleotide group Chemical group 0.000 claims description 43
- 239000013598 vector Substances 0.000 claims description 41
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 239000012634 fragment Substances 0.000 claims description 35
- 101710116435 Outer membrane protein Proteins 0.000 claims description 30
- 201000009182 Chikungunya Diseases 0.000 claims description 26
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 26
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 208000035473 Communicable disease Diseases 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 10
- 230000000890 antigenic effect Effects 0.000 claims description 10
- 210000000234 capsid Anatomy 0.000 claims description 10
- 230000003993 interaction Effects 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000003308 immunostimulating effect Effects 0.000 claims description 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 3
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 6
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 23
- 125000005647 linker group Chemical group 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 18
- 208000015181 infectious disease Diseases 0.000 description 16
- 229960005486 vaccine Drugs 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 13
- 108020001507 fusion proteins Proteins 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 230000003053 immunization Effects 0.000 description 11
- 238000002649 immunization Methods 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 11
- 102000040430 polynucleotide Human genes 0.000 description 11
- 239000002157 polynucleotide Substances 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 241000710929 Alphavirus Species 0.000 description 9
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- 102000048362 human PDCD1 Human genes 0.000 description 8
- 210000002706 plastid Anatomy 0.000 description 8
- 241000193830 Bacillus <bacterium> Species 0.000 description 7
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 241000710831 Flavivirus Species 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 108091005573 modified proteins Proteins 0.000 description 6
- 102000035118 modified proteins Human genes 0.000 description 6
- 108090000565 Capsid Proteins Proteins 0.000 description 5
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 5
- 101710172711 Structural protein Proteins 0.000 description 5
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 5
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 5
- 241000710772 Yellow fever virus Species 0.000 description 5
- 239000003636 conditioned culture medium Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 229940051021 yellow-fever virus Drugs 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 241000725619 Dengue virus Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 241000224466 Giardia Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 101001117316 Mus musculus Programmed cell death 1 ligand 1 Proteins 0.000 description 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 3
- 241000125945 Protoparvovirus Species 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 102000048776 human CD274 Human genes 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 241000224489 Amoeba Species 0.000 description 2
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 241000710946 Barmah Forest virus Species 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 206010006143 Brain stem glioma Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 241000222178 Candida tropicalis Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 241000223782 Ciliophora Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 241000709687 Coxsackievirus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241000353621 Eilat virus Species 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 201000001342 Fallopian tube cancer Diseases 0.000 description 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 101710125507 Integrase/recombinase Proteins 0.000 description 2
- 241000701460 JC polyomavirus Species 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 208000004554 Leishmaniasis Diseases 0.000 description 2
- 206010024238 Leptospirosis Diseases 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 241000235395 Mucor Species 0.000 description 2
- 241000235388 Mucorales Species 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 241000526686 Paracoccidioides brasiliensis Species 0.000 description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 2
- 208000002471 Penile Neoplasms Diseases 0.000 description 2
- 206010034299 Penile cancer Diseases 0.000 description 2
- 241000235645 Pichia kudriavzevii Species 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 241000223810 Plasmodium vivax Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 241000606701 Rickettsia Species 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 241000710799 Rubella virus Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 2
- 241000223109 Trypanosoma cruzi Species 0.000 description 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 2
- 206010046431 Urethral cancer Diseases 0.000 description 2
- 206010046458 Urethral neoplasms Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 206010047741 Vulval cancer Diseases 0.000 description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 2
- 241000710886 West Nile virus Species 0.000 description 2
- 241000710951 Western equine encephalitis virus Species 0.000 description 2
- 241000222126 [Candida] glabrata Species 0.000 description 2
- 201000005188 adrenal gland cancer Diseases 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000010425 asbestos Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 208000032343 candida glabrata infection Diseases 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 2
- 208000026037 malignant tumor of neck Diseases 0.000 description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000012121 regulation of immune response Effects 0.000 description 2
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229910052895 riebeckite Inorganic materials 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 206010046885 vaginal cancer Diseases 0.000 description 2
- 208000013139 vaginal neoplasm Diseases 0.000 description 2
- 201000005102 vulva cancer Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- CULQNACJHGHAER-UHFFFAOYSA-N 1-[4-[(2-iodoacetyl)amino]benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=C(NC(=O)CI)C=C1 CULQNACJHGHAER-UHFFFAOYSA-N 0.000 description 1
- 241000235389 Absidia Species 0.000 description 1
- 241000224424 Acanthamoeba sp. Species 0.000 description 1
- 241000549363 Acanthomorphata Species 0.000 description 1
- 241000178568 Aura virus Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000231314 Babanki virus Species 0.000 description 1
- 241000223848 Babesia microti Species 0.000 description 1
- 241001235572 Balantioides coli Species 0.000 description 1
- 241000608319 Bebaru virus Species 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 241000868138 Cabassou virus Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229940124957 Cervarix Drugs 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 241000295636 Cryptosporidium sp. Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000465885 Everglades virus Species 0.000 description 1
- 241000231322 Fort Morgan virus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229940124897 Gardasil Drugs 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 241000608297 Getah virus Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000710948 Highlands J virus Species 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 101100407305 Homo sapiens CD274 gene Proteins 0.000 description 1
- 101100407307 Homo sapiens PDCD1LG2 gene Proteins 0.000 description 1
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000231318 Kyzylagach virus Species 0.000 description 1
- 241001245510 Lambia <signal fly> Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- 241000608292 Mayaro virus Species 0.000 description 1
- 241000763097 Me Tri virus Species 0.000 description 1
- 241001599018 Melanogaster Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000710949 Middelburg virus Species 0.000 description 1
- 241000465889 Mosso das Pedras virus Species 0.000 description 1
- 241000868135 Mucambo virus Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000224438 Naegleria fowleri Species 0.000 description 1
- 241000608287 Ndumu virus Species 0.000 description 1
- 235000007413 Nigella arvensis Nutrition 0.000 description 1
- 244000090896 Nigella sativa Species 0.000 description 1
- 235000016698 Nigella sativa Nutrition 0.000 description 1
- 241001126259 Nippostrongylus brasiliensis Species 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 241000710944 O'nyong-nyong virus Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001057811 Paracoccus <mealybug> Species 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 241000868134 Pixuna virus Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 102220468946 Protein unc-13 homolog A_K64A_mutation Human genes 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 1
- 229940124942 Recombivax HB Drugs 0.000 description 1
- 108700033496 Recombivax HB Proteins 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 241000328499 Rio Negro virus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- 241001660014 Salmon pancreas disease virus Species 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 241001472492 Southern elephant seal virus Species 0.000 description 1
- 241001149962 Sporothrix Species 0.000 description 1
- 241000868137 Tonate virus Species 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241000951300 Trocara virus Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 241000223105 Trypanosoma brucei Species 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 241000608278 Una virus Species 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 241000231320 Whataroa virus Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- DVKFVGVMPLXLKC-PUGXJXRHSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)[C@@]1(OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DVKFVGVMPLXLKC-PUGXJXRHSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000007456 balantidiasis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 208000025698 brain inflammatory disease Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- LVXHNCUCBXIIPE-UHFFFAOYSA-L disodium;hydrogen phosphate;hydrate Chemical compound O.[Na+].[Na+].OP([O-])([O-])=O LVXHNCUCBXIIPE-UHFFFAOYSA-L 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 1
- 102000048119 human PDCD1LG2 Human genes 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002766 immunoenhancing effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000001595 mastoid Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 102220049431 rs587784257 Human genes 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- ULARYIUTHAWJMU-UHFFFAOYSA-M sodium;1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O ULARYIUTHAWJMU-UHFFFAOYSA-M 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- MIDXXTLMKGZDPV-UHFFFAOYSA-M sodium;1-[6-(2,5-dioxopyrrol-1-yl)hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O MIDXXTLMKGZDPV-UHFFFAOYSA-M 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- -1 sulfo-SMPB Chemical compound 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 201000011294 ureter cancer Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361845712P | 2013-07-12 | 2013-07-12 | |
| US61/845,712 | 2013-07-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201536812A TW201536812A (zh) | 2015-10-01 |
| TWI676636B true TWI676636B (zh) | 2019-11-11 |
Family
ID=52277262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103123759A TWI676636B (zh) | 2013-07-12 | 2014-07-10 | 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9637532B2 (enExample) |
| EP (2) | EP3019600B1 (enExample) |
| JP (1) | JP6557208B2 (enExample) |
| KR (1) | KR20160029124A (enExample) |
| CN (1) | CN105358683A (enExample) |
| AR (1) | AR096885A1 (enExample) |
| AU (1) | AU2014288147B2 (enExample) |
| BR (1) | BR112016000303A2 (enExample) |
| CA (1) | CA2916458A1 (enExample) |
| IL (1) | IL243304B (enExample) |
| MX (1) | MX364952B (enExample) |
| TW (1) | TWI676636B (enExample) |
| WO (1) | WO2015005500A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX357202B (es) | 2012-02-16 | 2018-06-28 | Vlp Therapeutics Llc | Composicion de particula tipo virus. |
| US9637532B2 (en) | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| CA2942245C (en) | 2014-03-12 | 2021-11-02 | Yeda Research And Development Co. Ltd. | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| EP3177720B1 (en) | 2014-08-08 | 2021-09-22 | VLP Therapeutics, Inc. | Virus like particle comprising modified envelope protein e3 |
| US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| KR102532832B1 (ko) | 2014-09-11 | 2023-05-16 | 브이엘피 테라퓨틱스 인코포레이티드 | 플라비바이러스 바이러스 유사 입자 |
| CN107530410B (zh) * | 2015-03-18 | 2021-11-09 | 欧姆尼赛特有限公司 | 包含经修饰的α病毒表面糖蛋白与肿瘤相关抗原的融合蛋白及其方法 |
| US10166281B2 (en) * | 2015-09-04 | 2019-01-01 | Vlp Therapeutics, Llc | Method and composition for modulating immune response |
| WO2018067361A1 (en) * | 2016-10-04 | 2018-04-12 | The Curators Of The University Of Missouri | Peptides for molecular detection of pd-l1 |
| EP3589312A1 (en) | 2017-03-03 | 2020-01-08 | New York University | Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins |
| SG11201908528UA (en) | 2017-03-17 | 2019-10-30 | Vaximm Ag | Novel pd-l1 targeting dna vaccine for cancer immunotherapy |
| JP7346302B2 (ja) * | 2017-03-28 | 2023-09-19 | オハイオ・ステイト・イノベーション・ファウンデーション | ヒトｐｄ－１ペプチドワクチン及びその使用法 |
| JP7412002B2 (ja) | 2017-12-20 | 2024-01-12 | ブイエルピー・セラピューティクス・インコーポレイテッド | アルファウイルスレプリコン粒子 |
| JP2021512966A (ja) * | 2018-02-07 | 2021-05-20 | イミュジーン、リミテッドＩｍｕｇｅｎｅ Ｌｉｍｉｔｅｄ | ワクチン組成物およびその使用 |
| FR3078535B1 (fr) * | 2018-03-05 | 2024-02-09 | Peptinov Sas | Composition vaccinale anti-pd-l1 |
| FR3078536A1 (fr) * | 2018-03-05 | 2019-09-06 | Peptinov Sas | Composition vaccinale anti-pd-1 |
| EP3762023A4 (en) * | 2018-03-05 | 2021-12-29 | New York University | Induction and enhancement of antitumor immunity involving sindbis virus vectors expressing immune checkpoint proteins |
| WO2020071869A1 (ko) * | 2018-10-05 | 2020-04-09 | 알엔에이진 주식회사 | 표적 세포 특이적으로 결합하여 다중 면역기능이 강화된 키메라항원 및 이의용도 |
| US12331096B2 (en) * | 2019-01-04 | 2025-06-17 | George Mason Research Foundation, Inc. | Binding domain mapping and compounds, compositions, complexes, methods, and kits related thereto |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| AU2020350666A1 (en) * | 2019-09-17 | 2022-03-31 | Ohio State Innovation Foundation | Human anti-PD-L1 peptide vaccines and methods of their use |
| CN111116733B (zh) * | 2019-11-28 | 2021-11-05 | 广东药科大学 | 一种靶向程序性死亡受体1和pd-1配体1相互作用界面的抗原肽和纳米抗体 |
| WO2021169673A1 (en) * | 2020-02-26 | 2021-09-02 | Versitech Limited | Pd-1-based vaccines against coronavirus infection |
| CN115867658A (zh) | 2020-04-17 | 2023-03-28 | Vlp治疗公司 | 冠状病毒疫苗 |
| EP4143323A4 (en) | 2020-04-30 | 2025-01-08 | VLP Therapeutics, Inc. | CYTOKINE IMMUNOTHERAPY |
| JPWO2024111633A1 (enExample) * | 2022-11-24 | 2024-05-30 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101151272A (zh) * | 2003-12-01 | 2008-03-26 | 陶氏环球技术公司 | 在假单胞菌中生产重组二十面体病毒样颗粒 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8923123D0 (en) | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
| AU2927892A (en) | 1991-11-16 | 1993-06-15 | Smithkline Beecham Biologicals (Sa) | Hybrid protein between cs from plasmodium and hbsag |
| US5580773A (en) | 1992-06-17 | 1996-12-03 | Korea Green Cross Corporation | Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV) |
| CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
| AU716466B2 (en) | 1995-09-27 | 2000-02-24 | Medical Research Council | Recombinant viruses incorporating a protease cleavable protein |
| EP1054973A1 (en) | 1998-02-11 | 2000-11-29 | Maxygen, Inc. | Antigen library immunization |
| HU228477B1 (en) * | 1999-08-23 | 2013-03-28 | Dana Farber Cancer Inst Inc | Pd-1, a receptor for b7-4, and uses therefor |
| US20110262389A1 (en) | 2001-02-13 | 2011-10-27 | Mosca Joseph D | Tumor-derived Biological Antigen Presenting Particles |
| AU2002344190B2 (en) | 2001-05-30 | 2007-10-18 | Transgene S.A. | Adenovirus protein IX, Its domains involved in capsid assembly, transcriptional activity and nuclear reorganization |
| CA2460269C (en) | 2001-09-06 | 2013-01-15 | Alphavax, Inc. | Alphavirus replicon vector systems |
| US7476390B2 (en) | 2002-02-26 | 2009-01-13 | Maxygen, Inc. | Flavivirus antigens |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| EP1583500A4 (en) | 2002-11-13 | 2008-02-13 | Us Navy | METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSES AND PROTEIN IMMUNITY BY PRIMARY IMMUNIZATION WITH ALPHAVIRUS REPLICON VACCINES |
| ES2552687T3 (es) | 2002-12-13 | 2015-12-01 | Alphavax, Inc. | Partículas alfavíricas y métodos de preparación |
| US7442381B2 (en) | 2003-03-20 | 2008-10-28 | Alphavax, Inc. | Alphavirus replicons and helper constructs |
| MXPA05012754A (es) | 2003-05-29 | 2006-05-17 | Army Medical Res Inst For I | Vacunas virales atenuadas vivas para virus de encefalitis equina oriental. |
| PT1751289E (pt) | 2004-05-18 | 2009-03-31 | Alphavax Inc | Vectores de alfavirais derivados da tc-83, partículas e métodos |
| RS52187B (sr) | 2004-10-14 | 2012-10-31 | Crucell Holland B.V. | Vakcine za indukciju i stimulaciju imunskog odgovora za malariju |
| US20090298955A1 (en) | 2005-02-16 | 2009-12-03 | Konica Minolta Holdings, Inc. | Altered virus capsid protein and use thereof |
| SG10201702670VA (en) * | 2005-06-08 | 2017-06-29 | Dana Farber Cancer Inst Inc | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway |
| GB0513421D0 (en) | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
| US20070104689A1 (en) | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| CU23586A1 (es) | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
| US8216996B2 (en) | 2006-03-03 | 2012-07-10 | Ono Pharmaceutical Co., Ltd. | Multimer of extracellular domain of cell surface functional molecule |
| US7499304B2 (en) | 2006-07-31 | 2009-03-03 | Sandisk 3D Llc | Systems for high bandwidth one time field-programmable memory |
| AU2007291936B2 (en) | 2006-08-30 | 2012-09-27 | Artes Biotechnology Gmbh | Recombinant proteins and virus like particles comprising L and S polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same |
| GB2453155A (en) | 2007-09-26 | 2009-04-01 | Rolls Royce Plc | Co-axial pipe assembly which supplies oil to a bearing in a gas turbine engine |
| US20110035004A1 (en) | 2007-11-14 | 2011-02-10 | Maxwell G | Interfaced medical implant |
| AU2008338803B2 (en) | 2007-11-26 | 2015-02-05 | Glaxosmithkline Biologicals S.A. | Methods of generating alphavirus particles |
| CN102317308A (zh) | 2008-11-26 | 2012-01-11 | 美国国有健康与人类服务部 | 类病毒组合物颗粒及其使用方法 |
| CN102695524B (zh) | 2009-09-18 | 2014-07-09 | 弗劳恩霍费尔美国股份有限公司 | 包含与植物病毒衣壳蛋白融合的靶蛋白的病毒样颗粒 |
| US8907053B2 (en) * | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2012006180A1 (en) | 2010-06-29 | 2012-01-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv immunogens |
| WO2012008561A1 (ja) | 2010-07-13 | 2012-01-19 | 帝人株式会社 | 炭素繊維束及びその製造方法、ならびにそれからの成形品 |
| WO2012023995A1 (en) | 2010-08-18 | 2012-02-23 | Takayuki Shiratsuchi | Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes |
| WO2012106356A2 (en) | 2011-01-31 | 2012-08-09 | GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | Virus-like particles and methods of use |
| JP6130307B2 (ja) | 2011-03-17 | 2017-05-17 | ザ ユニバーシティ オブ バーミンガム | 再指向性免疫療法 |
| BR112013032251B1 (pt) | 2011-06-17 | 2021-12-07 | Bharat Biotech International Limited | Composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações, uso de isolados do vírus chikungunya, e composição combinada da vacina |
| WO2013009884A1 (en) | 2011-07-12 | 2013-01-17 | The Government Of The United States America As Represented By The Secretary Of The Department Of Health And Human Services | Identification of a west nile virus cd4 t cell epitope and use thereof |
| CN102321639B (zh) | 2011-09-08 | 2013-06-26 | 中国疾病预防控制中心病毒病预防控制所 | 基孔肯雅病毒病毒样颗粒的制备方法和应用 |
| LT2768524T (lt) * | 2011-10-17 | 2022-07-25 | Io Biotech Aps | Pd-l1 grindžiama imunoterapija |
| US20150265694A1 (en) | 2011-10-25 | 2015-09-24 | Florida Gulf Coast University Board Of Trustees | Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes |
| MX357202B (es) * | 2012-02-16 | 2018-06-28 | Vlp Therapeutics Llc | Composicion de particula tipo virus. |
| BR112014024612A2 (pt) | 2012-04-02 | 2021-06-08 | Univ North Carolina Chapel Hill | ácido nucleico, polipeptídeo, glicoproteína e quimérica, epítopo de vírus da dengue, partícula semelhante a flavivírus quimérico (vlp), flavivírus quimérico, e métodos in vitro para identificar um anticorpo neutralizante e para identificar uma composição imunogênica contra um vírus da dengue |
| HUE039215T2 (hu) * | 2012-05-16 | 2018-12-28 | Immune Design Corp | Vakcinák HSV-2-höz |
| KR102494564B1 (ko) | 2013-06-03 | 2023-01-31 | 브이엘피 테라퓨틱스 인코포레이티드 | 말라리아 백신 |
| US9637532B2 (en) | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
| EP3119801B1 (en) | 2014-03-18 | 2019-07-17 | Fraunhofer Gesellschaft zur Förderung der Angewand | Distinguishing flavivirus infection using a recombinant mutant envelope protein |
| US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| EP3177720B1 (en) | 2014-08-08 | 2021-09-22 | VLP Therapeutics, Inc. | Virus like particle comprising modified envelope protein e3 |
| KR102532832B1 (ko) | 2014-09-11 | 2023-05-16 | 브이엘피 테라퓨틱스 인코포레이티드 | 플라비바이러스 바이러스 유사 입자 |
| US9363353B1 (en) | 2014-12-04 | 2016-06-07 | Hon Man Ashley Chik | Mobile phone docks with multiple circulating phone connectors |
| WO2016109792A2 (en) | 2014-12-31 | 2016-07-07 | The Usa, As Represented By The Secretary, Detp. Of Health And Human Services | Novel multivalent nanoparticle-based vaccines |
| CN107849558A (zh) | 2015-06-12 | 2018-03-27 | 国立大学法人三重大学 | 2型人副流感病毒载体和疫苗 |
| US10799575B2 (en) | 2015-06-25 | 2020-10-13 | Technovax, Inc. | Flavivirus and alphavirus virus-like particles (VLPS) |
| KR20180036987A (ko) | 2015-07-16 | 2018-04-10 | 브하라트 바이오테크 인터내셔날 리미티드 | 백신 조성물 |
| EP4218805A1 (en) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Infectious disease vaccines |
| US10166281B2 (en) | 2015-09-04 | 2019-01-01 | Vlp Therapeutics, Llc | Method and composition for modulating immune response |
| WO2017150683A1 (en) | 2016-03-04 | 2017-09-08 | Vlp Therapeutics, Llc | Zika virus virus like particle |
| CN106085974B (zh) | 2016-06-07 | 2019-08-09 | 博奥生物集团有限公司 | 一种寨卡病毒假病毒颗粒及其制备方法 |
-
2014
- 2014-07-10 US US14/328,268 patent/US9637532B2/en not_active Expired - Fee Related
- 2014-07-10 TW TW103123759A patent/TWI676636B/zh not_active IP Right Cessation
- 2014-07-11 EP EP14823398.4A patent/EP3019600B1/en active Active
- 2014-07-11 EP EP19219213.6A patent/EP3666890A1/en not_active Withdrawn
- 2014-07-11 AR ARP140102570A patent/AR096885A1/es unknown
- 2014-07-11 KR KR1020167003373A patent/KR20160029124A/ko not_active Withdrawn
- 2014-07-11 BR BR112016000303A patent/BR112016000303A2/pt not_active Application Discontinuation
- 2014-07-11 WO PCT/JP2014/069122 patent/WO2015005500A1/en not_active Ceased
- 2014-07-11 MX MX2016000381A patent/MX364952B/es active IP Right Grant
- 2014-07-11 CA CA2916458A patent/CA2916458A1/en not_active Abandoned
- 2014-07-11 JP JP2016501252A patent/JP6557208B2/ja active Active
- 2014-07-11 CN CN201480039571.4A patent/CN105358683A/zh active Pending
- 2014-07-11 AU AU2014288147A patent/AU2014288147B2/en not_active Expired - Fee Related
-
2015
- 2015-12-23 IL IL243304A patent/IL243304B/en not_active IP Right Cessation
-
2017
- 2017-04-27 US US15/498,971 patent/US10464986B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101151272A (zh) * | 2003-12-01 | 2008-03-26 | 陶氏环球技术公司 | 在假单胞菌中生产重组二十面体病毒样颗粒 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016526374A (ja) | 2016-09-05 |
| EP3019600B1 (en) | 2019-12-25 |
| AU2014288147A1 (en) | 2016-01-21 |
| US20170233450A1 (en) | 2017-08-17 |
| KR20160029124A (ko) | 2016-03-14 |
| EP3019600A4 (en) | 2017-04-12 |
| BR112016000303A2 (pt) | 2017-12-12 |
| IL243304A0 (en) | 2016-03-31 |
| US20150017194A1 (en) | 2015-01-15 |
| EP3019600A1 (en) | 2016-05-18 |
| CA2916458A1 (en) | 2015-01-15 |
| MX2016000381A (es) | 2016-09-07 |
| EP3666890A1 (en) | 2020-06-17 |
| US9637532B2 (en) | 2017-05-02 |
| CN105358683A (zh) | 2016-02-24 |
| IL243304B (en) | 2020-02-27 |
| WO2015005500A1 (en) | 2015-01-15 |
| TW201536812A (zh) | 2015-10-01 |
| AU2014288147B2 (en) | 2020-04-09 |
| MX364952B (es) | 2019-05-14 |
| US10464986B2 (en) | 2019-11-05 |
| JP6557208B2 (ja) | 2019-08-07 |
| AR096885A1 (es) | 2016-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI676636B (zh) | 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子 | |
| JP6824154B2 (ja) | 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子 | |
| TWI687442B (zh) | 瘧疾疫苗 | |
| Denis et al. | Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization | |
| US10385101B2 (en) | Virus like particle comprising modified envelope protein E3 | |
| US20130251744A1 (en) | Virus like particle composition | |
| JPH09501933A (ja) | 植物、動物、およびヒトのワクチンとして並びに免疫療法に有用な抗体の免疫優性エピトープの弱化 | |
| JP2011513399A (ja) | 同種癌細胞による免疫療法 | |
| JP7304421B2 (ja) | 標的細胞特異的に結合して多重免疫機能が強化されたキメラ抗原及びこの用途 | |
| KR20250094574A (ko) | 변이 rsv 단백질 | |
| OA17590A (en) | Malaria Vaccine | |
| HK1187829A (en) | Adjuvant compositions with 4-1bbl |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |